Research Excellence Award
Cleophas Mutinda Kyama
Jomo Kenyatta University of Agriculture and Technology, Kenya
Cleophas Mutinda Kyama is a Kenyan biomedical scientist, clinical cytologist, and academic researcher associated with the Jomo Kenyatta University of Agriculture and Technology (JKUAT). His scholarly contributions span cancer biology, molecular diagnostics, parasitology, toxicology, infectious disease detection, and translational biomedical sciences. His publication record demonstrates sustained engagement in interdisciplinary health science research with applications in oncology, infectious diseases, immunology, and molecular medicine.[1] The researcher has received significant scholarly attention through citations and collaborative biomedical investigations, particularly in cervical cancer diagnostics, phytomedicine, CRISPR-based diagnostic technologies, and antivenom development.[2]
Abstract
The Research Excellence Award recognition article documents the scholarly achievements and biomedical research contributions of Cleophas Mutinda Kyama. His scientific portfolio encompasses molecular diagnostics, oncology, pharmacological investigations, parasitology, immunological research, and translational health sciences. Through peer-reviewed publications, collaborative international research, and laboratory-based innovations, Kyama has contributed to the advancement of diagnostic technologies and therapeutic investigations relevant to public health challenges in Africa and globally.[3] The researcher’s work demonstrates integration of computational biology, molecular docking, in vitro experimentation, and nanotechnology-assisted diagnostics, reflecting contemporary interdisciplinary scientific approaches.[4]
Keywords
Biomedical Sciences; Molecular Diagnostics; Cervical Cancer Research; CRISPR-Cas12a; Oncology; Cytology; Antivenom Research; Pharmacology; Translational Medicine; Public Health Research; Cancer Therapeutics; Computational Biology.
Introduction
Biomedical and translational health sciences have increasingly relied upon interdisciplinary approaches integrating molecular biology, computational modeling, immunology, and experimental medicine. Within this scientific landscape, Cleophas Mutinda Kyama has contributed to research efforts addressing infectious diseases, cancer diagnostics, toxicology, and therapeutic screening technologies.[5] His work has emphasized practical healthcare applications, particularly within African biomedical contexts where diagnostic accessibility and disease management remain major public health priorities.
Kyama’s research trajectory demonstrates sustained engagement in clinically relevant investigations involving HPV-associated cervical cancer screening, SARS-CoV-2 detection systems, phytochemical anticancer studies, and venom toxicology. Several of his investigations combine computational methodologies with laboratory validation, contributing to evidence-based biomedical innovation and translational healthcare research.[6]
Research Profile
Cleophas Mutinda Kyama served at Jomo Kenyatta University of Agriculture and Technology as a Biomedical Scientist and Senior Lecturer in Medical Laboratory Sciences. His academic and professional work has focused on laboratory diagnostics, cytology, cancer biology, molecular therapeutics, and pathogen detection technologies.[1]
The researcher’s Scopus profile reports 65 scholarly documents with 2,698 citations and an h-index of 29, reflecting measurable scientific visibility and sustained citation impact across biomedical disciplines.[1] His work has appeared in journals including PLOS ONE, BMC Complementary Medicine and Therapies, Diagnostics, Toxicon: X, Toxins, and the South African Journal of Botany.
- Research specialization in molecular diagnostics and biomedical laboratory sciences.
- Interdisciplinary research combining computational biology and experimental medicine.
- Published investigations involving oncology, toxicology, parasitology, and virology.
- Contributions to public health-oriented biomedical innovation.
Research Contributions
Among Kyama’s notable scientific contributions are investigations into cervical cancer therapeutics and molecular screening technologies. His 2025 study in PLOS ONE explored the molecular mechanisms of Solanecio mannii aqueous root extracts against cervical cancer using computational and experimental validation methodologies.[2]
Additional research explored network pharmacology and molecular docking strategies for prostate cancer treatment investigations using Aspilia pluriseta. These studies integrated in vitro analysis with computational biology techniques to evaluate antiproliferative activity and potential therapeutic mechanisms.[3]
Kyama also contributed to advanced infectious disease diagnostics through CRISPR-Cas12a and hybridization chain reaction methodologies for SARS-CoV-2 detection. This work reflected the growing importance of rapid molecular diagnostic systems during global public health emergencies.[4]
In toxicological and immunological sciences, his studies investigated venom lethality, monoclonal antibody development, and antivenom efficacy involving Naja ashei toxins. These investigations contributed to understanding envenomation management and toxin-neutralizing biomedical strategies.[7]
Publications
Selected publications associated with Cleophas Mutinda Kyama include peer-reviewed journal articles, preprints, and translational biomedical studies relevant to oncology, diagnostics, toxicology, and parasitology.
- Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE (2025).
- Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies (2024).
- Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics (2023).
- Evaluation of lethality and cytotoxic effects induced by Naja ashei venom and efficacy of selected antivenoms in Kenya. Toxicon: X (2022).
- Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins (2022).
Research Impact
The scientific impact of Cleophas Mutinda Kyama’s work is reflected through citation metrics, interdisciplinary collaborations, and practical biomedical applications. His investigations into molecular diagnostics and therapeutic evaluation contribute to contemporary discussions surrounding affordable healthcare technologies, precision diagnostics, and evidence-based medicinal research.[4]
Research involving CRISPR-based diagnostics and nanoparticle-assisted detection systems demonstrates alignment with emerging biomedical technologies that support rapid pathogen identification and translational healthcare innovation.[8] Similarly, his toxicological and antivenom studies address healthcare concerns related to snakebite management in endemic regions.
The integration of phytomedicine, computational molecular analysis, and laboratory validation techniques further reflects a multidisciplinary scientific framework capable of supporting future biomedical innovation and collaborative translational research initiatives.[3]
Award Suitability
The scholarly profile of Cleophas Mutinda Kyama demonstrates characteristics associated with international academic recognition and research excellence awards. His documented publication history, citation impact, interdisciplinary biomedical investigations, and sustained engagement in translational health sciences collectively support recognition within the framework of the Global Innovation Technologist Awards.[1]
- Demonstrated publication productivity in indexed scientific journals.
- Strong citation impact and measurable academic influence.
- Contributions to molecular diagnostics and translational medicine.
- Interdisciplinary biomedical innovation relevant to public health.
- Research engagement involving computational and experimental methodologies.
Conclusion
Cleophas Mutinda Kyama has established a research profile characterized by interdisciplinary biomedical inquiry, molecular diagnostic innovation, and translational scientific investigations addressing major health challenges. His academic contributions in oncology, toxicology, molecular biology, and infectious disease diagnostics demonstrate sustained scholarly engagement and measurable scientific impact.[5] Through collaborative biomedical research and publication activity, his work contributes to evolving scientific understanding within medicine and health sciences while supporting broader healthcare research objectives relevant to emerging global health priorities.
External Links
References
- Elsevier. (n.d.). Scopus author details: Cleophas Mutinda Kyama, Author ID 57216717397. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=57216717397
- Kyama, C. M. et al. (2025). Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE.
https://doi.org/10.1371/journal.pone.0323680
- Kyama, C. M. et al. (2024). Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies.
https://doi.org/10.1186/s12906-024-04642-8
- Kyama, C. M. et al. (2023). Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics.
https://doi.org/10.3390/diagnostics13091644
- Jomo Kenyatta University of Agriculture and Technology. (n.d.). Medical Laboratory Sciences and Biomedical Research Activities.
- Kyama, C. M. et al. (2022). Expression of the Fab enzymes from Plasmodium falciparum after exposure to Artemisia afra plant extracts. Journal of Parasitic Diseases.
https://doi.org/10.1007/s12639-022-01537-8
- Kyama, C. M. et al. (2022). Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins.
https://doi.org/10.3390/toxins14040285
- Kyama, C. M. et al. (2020). Development of HPV 16/18 E6 oncoprotein paper-based nanokit for enhanced cervical cancer screening.
https://doi.org/10.1101/2020.04.29.20084459